ANO1 and head and neck squamous cell carcinoma: To explore a potential association of ANO1 expression in HNSCC with clinical susceptibility to EGFR inhibitors, we tested a panel of HNSCC cell lines for sensitivity to Gefitinib and measured expression of EGFR and ANO1 using quantitative PCR and western blotting (Figure 5A and 5B).